AU
UK
CA
NZ
IND
US
UroGen Pharma Expands Clinical Engagement in LG-UTUC Treatment LandscapeUroGen Pharma Ltd. has introduced its “LG-UTUC Luminaries” initiative, a clinician- and institution-focused program aimed at advancing care standards for low-grade upper tract urothelial cancer (LG-UTUC). The initiative underscores the company’s broader strategy of embedding itself …
Single-Patient Case Study Highlights Early Signal for Phyto-N in Cancer CachexiaCuranex Pharmaceuticals drew market attention after presenting a single-patient case study suggesting potential symptomatic benefits of its lead candidate, Phyto-N, in cancer cachexia and advanced cancer supportive care. The patient, treated for a pancreatic …
BioXcel Therapeutics has initiated patient enrollment in a Phase 2a clinical trial evaluating BXCL501 for acute stress reactions (ASR), marking a notable step in the company’s effort to expand its neuroscience pipeline. The study, funded by the U.S. Department of War and led by …
AI Nose Healthcare Deployment Signals Strategic Expansion into High-Value InfrastructureAinos, Inc. (NASDAQ: AIMD) has announced a partnership with MacKay Memorial Hospital and Topco Scientific to deploy its AI Nose technology across critical hospital environments. This move marks a notable extension of its Smell AI …
Capital Raising and Liquidity Position Strengthen Acquisition Pipeline
enGene Therapeutics Name Change Reflects Commercial Transition StrategyenGene’s decision to rebrand from enGene Holdings Inc. to enGene Therapeutics Inc. marks a strategic inflection point as the company moves closer to potential commercialization. The name change, effective April 8, 2026, aligns with its evolving identity …
Crypto Reconnects with Macro Signals
A Sudden Shift in Market Sentiment
The electronic technology sector delivered one of its most synchronised advances in recent memory, with virtually every corner of the hardware supply chain posting robust gains as investors reconsidered the durability of artificial intelligence-driven capital expenditure and the prospects for a recovery in the …
A Policy Built on Leverage, Not Price Controls
Please wait processing your request...